Literature DB >> 17033640

Genentech raises stakes on PARP inhibitors.

Cormac Sheridan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17033640     DOI： 10.1038/nbt1006-1179

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  PARP inhibitors blaze a trail in difficult-to-treat cancers.

Authors:  Jim Kling
Journal:  Nat Biotechnol       Date:  2009-09       Impact factor: 54.908

Review 2.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 3.  Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation.

Authors:  April M Reed; Melissa L Fishel; Mark R Kelley
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

4.  Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Authors:  Ruth Plummer; Christopher Jones; Mark Middleton; Richard Wilson; Jeffrey Evans; Anna Olsen; Nicola Curtin; Alan Boddy; Peter McHugh; David Newell; Adrian Harris; Patrick Johnson; Heidi Steinfeldt; Raz Dewji; Diane Wang; Lesley Robson; Hilary Calvert
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.